These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27311087)

  • 41. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
    [No Abstract]   [Full Text] [Related]  

  • 42. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 44. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared].
    Kostner KM; Kostner GM
    Wien Klin Wochenschr; 1998 Oct; 110(18):625-30. PubMed ID: 9816634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications.
    Azemawah V; Movahed MR; Centuori P; Penaflor R; Riel PL; Situ S; Shadmehr M; Hashemzadeh M
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):625-639. PubMed ID: 31773344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies to overcome statin intolerance.
    Agouridis AP; Nair DR; Mikhailidis DP
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New benefits of statin treatment.
    Boden G
    Curr Diab Rep; 2005 Jun; 5(3):165; discussion 165-6. PubMed ID: 15929860
    [No Abstract]   [Full Text] [Related]  

  • 51. High-dose statin therapy: benefits and safety in aggressive lipid lowering.
    Toth PP; Davidson MH
    J Fam Pract; 2008 May; 57(5 Suppl High-Dose):S29-36. PubMed ID: 18662521
    [No Abstract]   [Full Text] [Related]  

  • 52. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Achieving target cholesterol levels in diabetic patients: potency of the statin or potency of the physician?
    Shani M; Dresner J; Vinker S
    Isr Med Assoc J; 2008 May; 10(5):354-7. PubMed ID: 18605358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
    Rosenson RS; Baker S; Banach M; Borow KM; Braun LT; Bruckert E; Brunham LR; Catapano AL; Elam MB; Mancini GBJ; Moriarty PM; Morris PB; Muntner P; Ray KK; Stroes ES; Taylor BA; Taylor VH; Watts GF; Thompson PD
    J Am Coll Cardiol; 2017 Sep; 70(10):1290-1301. PubMed ID: 28859793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The nurse practitioner's role in helping patients achieve lipid goals with statin therapy.
    Mason CM
    J Am Acad Nurse Pract; 2005 Jul; 17(7):256-62. PubMed ID: 15982245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of the patient with statin intolerance.
    Vandenberg BF; Robinson J
    Curr Atheroscler Rep; 2010 Jan; 12(1):48-57. PubMed ID: 20425271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statin Intolerance: A Literature Review and Management Strategies.
    Saxon DR; Eckel RH
    Prog Cardiovasc Dis; 2016; 59(2):153-164. PubMed ID: 27497504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipid-lowering drugs and control of hypercholesterolemia in Poland: recent evidence.
    Jankowski P; Kloch-Badełek M; Dębicka-Dąbrowska D
    Pol Arch Med Wewn; 2011 May; 121(5):164-71. PubMed ID: 21610664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Statin intolerance].
    Graversen CB; Larsen ML; Schmidt EB
    Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.